Skip to main content

Articles

Page 1 of 108

  1. Little is known about how use of chemotherapy has evolved in breast cancer patients. We therefore describe chemotherapy patterns for women with stage I-IIIA breast cancer in the Optimal Breast Cancer Chemother...

    Authors: Jenna Bhimani, Kelli O’Connell, Isaac J. Ergas, Marilyn Foley, Grace B. Gallagher, Jennifer J. Griggs, Narre Heon, Tatjana Kolevska, Yuriy Kotsurovskyy, Candyce H. Kroenke, Cecile. A. Laurent, Raymond Liu, Kanichi G. Nakata, Sonia Persaud, Donna R. Rivera, Janise M. Roh…
    Citation: Breast Cancer Research 2024 26:101
  2. Immunohistochemistry (IHC) and in situ hybridization (ISH) remain standard biomarkers for therapeutic decisions in human epidermal growth factor 2 (HER2)-positive breast cancers (BCs); however, they are insuff...

    Authors: Huang-Chun Lien, Chiao Lo, Yi-Hsuang Lee, Po-Hang Lin, Ming-Yang Wang, Wen-Hung Kuo, Li-Wei Tsai, Yen-Shen Lu, Hsiang-Wei Hu, Yu-Chia Li and Chiun-Sheng Huang
    Citation: Breast Cancer Research 2024 26:100
  3. In this study, we prepared a bionic nanosystem of trastuzumab-functionalized SK-BR-3 cell membrane hybrid liposome-coated pyrotinib (Ptb-M-Lip-Her) for the treatment of HER2-positive breast cancer. Transmissio...

    Authors: Jiaqun Du, Xiaobang Liu, Junpeng Sun, Qian Wu, Yu Hu, Huan Shi, Li Zheng, Ying Liu, Chao Wu and Yu Gao
    Citation: Breast Cancer Research 2024 26:99
  4. Tumor immune infiltration and peripheral blood immune signatures have prognostic and predictive value in breast cancer. Whether distinct peripheral blood immune phenotypes are associated with response to neoad...

    Authors: Roberto A. Leon-Ferre, Kaitlyn R. Whitaker, Vera J. Suman, Tanya Hoskin, Karthik V. Giridhar, Raymond M. Moore, Ahmad Al-Jarrad, Sarah A. McLaughlin, Donald W. Northfelt, Katie N. Hunt, Amy Lynn Conners, Ann Moyer, Jodi M. Carter, Krishna Kalari, Richard Weinshilboum, Liewei Wang…
    Citation: Breast Cancer Research 2024 26:97
  5. Metabolic plasticity mediates breast cancer survival, growth, and immune evasion during metastasis. However, how tumor cell metabolism is influenced by and feeds back to regulate breast cancer progression are ...

    Authors: Michael F. Coleman, Eylem Kulkoyluoglu Cotul, Alexander J. Pfeil, Emily N. Devericks, Muhammad H. Safdar, Marvis Monteiro, Hao Chen, Alyssa N. Ho, Numair Attaar, Hannah M. Malian, Violet A. Kiesel, Alexis Ramos, Matthew Smith, Heena Panchal, Adam Mailloux, Dorothy Teegarden…
    Citation: Breast Cancer Research 2024 26:96
  6. Breast cancers treated with aromatase inhibitors (AIs) can develop AI resistance, which is often driven by estrogen receptor-alpha (ERα/ESR1) activating mutations, as well as by ER-independent signaling pathways....

    Authors: Muriel Lainé, Marianne E Greene, Justyna D Kurleto, Grazyna Bozek, Tiffany Leng, Rosemary J Huggins, Barry S Komm and Geoffrey L Greene
    Citation: Breast Cancer Research 2024 26:95
  7. RNA m5C methylation has been extensively implicated in the occurrence and development of tumors. As the main methyltransferase, NSUN2 plays a crucial regulatory role across diverse tumor types. However, the preci...

    Authors: Xuran Zhang, Ke An, Xin Ge, Yuanyuan Sun, Jingyao Wei, Weihong Ren, Han Wang, Yueqin Wang, Yue Du, Lulu He, Ouwen Li, Shaoxuan Zhou, Yong Shi, Tong Ren, Yun-gui Yang, Quancheng Kan…
    Citation: Breast Cancer Research 2024 26:94
  8. Inflammation could be related to cancer-related cognitive impairment (CRCI) and might be used as a predictive marker of long-term CRCI. We evaluated associations between inflammatory markers assessed at diagno...

    Authors: Mylène Duivon, Justine Lequesne, Antonio Di Meglio, Caroline Pradon, Ines Vaz-Luis, Anne-Laure Martin, Sibille Everhard, Sophie Broutin, Olivier Rigal, Chayma Bousrih, Christelle Lévy, Florence Lerebours, Marie Lange and Florence Joly
    Citation: Breast Cancer Research 2024 26:93
  9. Identifying new targets in triple negative breast cancer (TNBC) remains critical. REG3A (regenerating islet-derived protein 3 A), a calcium-dependent lectin protein, was thoroughly investigated for its express...

    Authors: Xiaoxia Jin, Shuyun Yang, Xiaoyun Lu, Xudong Chen and Wencheng Dai
    Citation: Breast Cancer Research 2024 26:92
  10. The aberrant amplification of mammary luminal progenitors is at the origin of basal-like breast cancers associated with BRCA1 mutations. Integrins mediate cell–matrix adhesion and transmit mechanical and chemi...

    Authors: Marisa M. Faraldo, Mathilde Romagnoli, Loane Wallon, Pierre Dubus, Marie-Ange Deugnier and Silvia Fre
    Citation: Breast Cancer Research 2024 26:91
  11. Nottingham histological grade (NHG) is a well established prognostic factor in breast cancer histopathology but has a high inter-assessor variability with many tumours being classified as intermediate grade, N...

    Authors: Constance Boissin, Yinxi Wang, Abhinav Sharma, Philippe Weitz, Emelie Karlsson, Stephanie Robertson, Johan Hartman and Mattias Rantalainen
    Citation: Breast Cancer Research 2024 26:90
  12. Early-stage invasive ductal carcinoma displays high survival rates due to early detection and treatments. However, there is still a chance of relapse of 3–15% after treatment. The aim of this study was to unco...

    Authors: Pere Miquel Morla-Barcelo, David Laguna-Macarrilla, Octavi Cordoba, Gabriel Matheu, Jordi Oliver, Pilar Roca, Mercedes Nadal-Serrano and Jorge Sastre-Serra
    Citation: Breast Cancer Research 2024 26:89
  13. Associations between reproductive factors and risk of breast cancer differ by subtype defined by joint estrogen receptor (ER), progesterone receptor (PR), and HER2 expression status. Racial and ethnic differen...

    Authors: Esther M. John, Jocelyn Koo, Amanda I. Phipps, Teri A. Longacre, Allison W. Kurian, Sue A. Ingles, Anna H. Wu and Lisa M. Hines
    Citation: Breast Cancer Research 2024 26:88
  14. Despite progress understanding the mechanisms underlying tumor spread, metastasis remains a clinical challenge. We identified the choline-producing glycerophosphodiesterase, EDI3 and reported its association w...

    Authors: Annika Glotzbach, Katharina Rohlf, Anastasia Gonscharow, Simon Lüke, Özlem Demirci, Brigitte Begher-Tibbe, Nina Overbeck, Jörg Reinders, Cristina Cadenas, Jan G. Hengstler, Karolina Edlund and Rosemarie Marchan
    Citation: Breast Cancer Research 2024 26:87
  15. Copy number gains in genes coding for Rho activating exchange factors as well as losses affecting genes coding for RhoGAP proteins are common in breast cancer (BC), suggesting that elevated Rho signaling may p...

    Authors: Nandini Raghuram, E. Idil Temel, Toshihiro Kawamata, Katelyn J. Kozma, Amanda J. Loch, Wei Wang, Jessica R. Adams, William J. Muller and Sean E. Egan
    Citation: Breast Cancer Research 2024 26:86
  16. Abbreviated breast MRI (FAST MRI) is being introduced into clinical practice to screen women with mammographically dense breasts or with a personal history of breast cancer. This study aimed to optimise diagno...

    Authors: Lyn I. Jones, Andrea Marshall, Rebecca Geach, Premkumar Elangovan, Elizabeth O’Flynn, Tony Timlin, Sadie McKeown-Keegan, Janice Rose, Sarah Vinnicombe, Sian Taylor-Phillips, Mark Halling-Brown and Janet A. Dunn
    Citation: Breast Cancer Research 2024 26:85
  17. Authors: Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra…
    Citation: Breast Cancer Research 2024 26:83

    The original article was published in Breast Cancer Research 2024 26:69

  18. Patients with a Breast Imaging Reporting and Data System (BI-RADS) 4 mammogram are currently recommended for biopsy. However, 70–80% of the biopsies are negative/benign. In this study, we developed a deep lear...

    Authors: Chang Liu, Min Sun, Dooman Arefan, Margarita Zuley, Jules Sumkin and Shandong Wu
    Citation: Breast Cancer Research 2024 26:82
  19. The proportion of patients with breast cancer and obesity is increasing. While the therapeutic landscape of breast cancer has been expanding, we lack knowledge about the potential differential efficacy of most...

    Authors: Josephine Van Cauwenberge, Karen Van Baelen, Marion Maetens, Tatjana Geukens, Ha Linh Nguyen, Ines Nevelsteen, Ann Smeets, Anne Deblander, Patrick Neven, Stijn Koolen, Hans Wildiers, Kevin Punie and Christine Desmedt
    Citation: Breast Cancer Research 2024 26:81
  20. Cancer-related fatigue (CRF) is a pervasive, persistent, and distressing symptom experienced by cancer patients, for which few treatments are available. We investigated the efficacy and safety of infrared lase...

    Authors: Huijuan Mao, Ming Jin, Lulu Xie, Ni Mao, Xubo Shen, Junchao Chen, Xuefen Chen, Jun J. Mao and Xueyong Shen
    Citation: Breast Cancer Research 2024 26:80
  21. Mammographic density (MD) has been shown to be a strong and independent risk factor for breast cancer in women of European and Asian descent. However, the majority of Asian studies to date have used BI-RADS a...

    Authors: Shivaani Mariapun, Weang-Kee Ho, Mikael Eriksson, Nur Aishah Mohd Taib, Cheng-Har Yip, Kartini Rahmat, Per Hall and Soo-Hwang Teo
    Citation: Breast Cancer Research 2024 26:79
  22. Metastatic breast cancer is a leading cause of cancer death in woman. Current treatment options are often associated with adverse side effects and poor outcomes, demonstrating the need for effective new treatm...

    Authors: Adam Nelson, Nichole McMullen, Simon Gebremeskel, Roberto De Antueno, Duncan Mackenzie, Roy Duncan and Brent Johnston
    Citation: Breast Cancer Research 2024 26:78
  23. Early prediction of pathological complete response (pCR) is important for deciding appropriate treatment strategies for patients. In this study, we aimed to quantify the dynamic characteristics of dynamic cont...

    Authors: Xinyu Zhang, Xinzhi Teng, Jiang Zhang, Qingpei Lai and Jing Cai
    Citation: Breast Cancer Research 2024 26:77
  24. Breast cancer (BC) is the most commonly diagnosed cancer and the leading cause of cancer death among women globally. Despite advances, there is considerable variation in clinical outcomes for patients with non...

    Authors: Praveen-Kumar Raj-Kumar, Xiaoying Lin, Tao Liu, Lori A. Sturtz, Marina A. Gritsenko, Vladislav A. Petyuk, Tyler J. Sagendorf, Brenda Deyarmin, Jianfang Liu, Anupama Praveen-Kumar, Guisong Wang, Jason E. McDermott, Anil K. Shukla, Ronald J. Moore, Matthew E. Monroe, Bobbie-Jo M. Webb-Robertson…
    Citation: Breast Cancer Research 2024 26:76
  25. Tumor-associated macrophages (TAMs) are a prominent immune subpopulation in the tumor microenvironment that could potentially serve as therapeutic targets for breast cancer. Thus, it is important to characteri...

    Authors: Angela R. Omilian, Rikki Cannioto, Lucas Mendicino, Leighton Stein, Wiam Bshara, Bo Qin, Elisa V. Bandera, Nur Zeinomar, Scott I. Abrams, Chi-Chen Hong, Song Yao, Thaer Khoury and Christine B. Ambrosone
    Citation: Breast Cancer Research 2024 26:75
  26. The transcription factor TRPS1 is a context-dependent oncogene in breast cancer. In the mammary gland, TRPS1 activity is restricted to the luminal population and is critical during puberty and pregnancy. Its f...

    Authors: Marie Tollot-Wegner, Marco Jessen, KyungMok Kim, Adrián Sanz-Moreno, Nadine Spielmann, Valerie Gailus-Durner, Helmut Fuchs, Martin Hrabe de Angelis and Björn von Eyss
    Citation: Breast Cancer Research 2024 26:74
  27. Following a breast cancer diagnosis, it is uncertain whether women’s breast density knowledge influences their willingness to undergo pre-operative imaging to detect additional cancer in their breasts. We eval...

    Authors: Rebecca E. Smith, Brian L. Sprague, Louise M. Henderson, Karla Kerlikowske, Diana L. Miglioretti, Karen J. Wernli, Tracy Onega, Roberta M. diFlorio-Alexander and Anna N.A. Tosteson
    Citation: Breast Cancer Research 2024 26:73
  28. Breast cancer, the most prevalent cancer in women worldwide, faces treatment challenges due to drug resistance, posing a serious threat to patient survival. The present study aimed to identify the key molecule...

    Authors: Prakash Chaudhary, Kiran Yadav, Ho Jin Lee, Keon Wook Kang, Jongseo Mo and Jung-Ae Kim
    Citation: Breast Cancer Research 2024 26:72
  29. To compare the compartmentalized diffusion-weighted models, intravoxel incoherent motion (IVIM) and restriction spectrum imaging (RSI), in characterizing breast lesions and normal fibroglandular tissue.

    Authors: Litong He, Yanjin Qin, Qilan Hu, Zhiqiang Liu, Yunfei Zhang and Tao Ai
    Citation: Breast Cancer Research 2024 26:71
  30. Basal-like breast cancer (BLBC) is the most aggressive subtype of breast cancer due to its aggressive characteristics and lack of effective therapeutics. However, the mechanism underlying its aggressiveness re...

    Authors: Ruocen Liao, Xingyu Chen, Qianhua Cao, Longchang Bai, Chenglong Ma, Zhijun Dai and Chenfang Dong
    Citation: Breast Cancer Research 2024 26:70
  31. We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had...

    Authors: Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra…
    Citation: Breast Cancer Research 2024 26:69

    The Correction to this article has been published in Breast Cancer Research 2024 26:83

  32. Artificial intelligence (AI) algorithms for the independent assessment of screening mammograms have not been well established in a large screening cohort of Asian women. We compared the performance of screenin...

    Authors: Mi-ri Kwon, Yoosoo Chang, Soo-Youn Ham, Yoosun Cho, Eun Young Kim, Jeonggyu Kang, Eun Kyung Park, Ki Hwan Kim, Minjeong Kim, Tae Soo Kim, Hyeonsoo Lee, Ria Kwon, Ga-Young Lim, Hye Rin Choi, JunHyeok Choi, Shin Ho Kook…
    Citation: Breast Cancer Research 2024 26:68
  33. Breast cancer exhibits significant heterogeneity, manifesting in various subtypes that are critical in guiding treatment decisions. This study aimed to investigate the existence of distinct subtypes of breast ...

    Authors: Jia-Wern Pan, Mohana Ragu, Wei-Qin Chan, Siti Norhidayu Hasan, Tania Islam, Li-Ying Teoh, Suniza Jamaris, Mee-Hoong See, Cheng-Har Yip, Pathmanathan Rajadurai, Lai-Meng Looi, Nur Aishah Mohd Taib, Oscar M. Rueda, Carlos Caldas, Suet-Feung Chin, Joanna Lim…
    Citation: Breast Cancer Research 2024 26:67
  34. This study investigated the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST) in patients with initially high nodal burden.

    Authors: Soong June Bae, Jung Whan Chun, Sae Byul Lee, Jai Min Ryu, Seok Jin Nam, Joon Jeong, Hyung Seok Park and Sung Gwe Ahn
    Citation: Breast Cancer Research 2024 26:66
  35. Sentinel lymph node biopsy (SLNB) is recommended for patients with ductal carcinoma in situ (DCIS) undergoing mastectomy, given the concerns regarding upstaging and technical difficulties of post-mastectomy SL...

    Authors: Soong June Bae, Yoonwon Kook, Ji Soo Jang, Seung Ho Baek, Sohyun Moon, Jung Hyun Kim, Seung Eun Lee, Min Ji Kim, Sung Gwe Ahn and Joon Jeong
    Citation: Breast Cancer Research 2024 26:65
  36. This study aimed to explore potential indicators associated with the neoadjuvant efficacy of TCbHP regimen (taxane, carboplatin, trastuzumab, and pertuzumab) in HER2 + breast cancer (BrCa) patients.

    Authors: Ningning Zhang, Yuxin Huang, Guanwen Wang, Yimei Xiang, Zhouhong Jing, Junjie Zeng, Feng Yu, Xianjun Pan, Wenqi Zhou and Xiaohua Zeng
    Citation: Breast Cancer Research 2024 26:64
  37. Chitinase-like proteins (CLPs) play a key role in immunosuppression under inflammatory conditions such as cancer. CLPs are enzymatically inactive and become neutralized upon binding of their natural ligand chi...

    Authors: Robbe Salembier, Caro De Haes, Julie Bellemans, Kristel Demeyere, Wim Van Den Broeck, Niek N. Sanders, Steven Van Laere, Traci R. Lyons, Evelyne Meyer and Jonas Steenbrugge
    Citation: Breast Cancer Research 2024 26:63
  38. Breast cancers exhibit considerable heterogeneity in their biology, immunology, and prognosis. Currently, no validated, serum protein-based tools are available to evaluate the prognosis of patients with early ...

    Authors: Peeter Karihtala, Suvi-Katri Leivonen, Ulla Puistola, Elina Urpilainen, Anniina Jääskeläinen, Sirpa Leppä and Arja Jukkola
    Citation: Breast Cancer Research 2024 26:61
  39. Small nucleolar RNAs (snoRNAs) play key roles in ribosome biosynthesis. However, the mechanism by which snoRNAs regulate cancer stemness remains to be fully elucidated.

    Authors: Wenrong Zhang, Xinyue Song, Zining Jin, Yiqi Zhang, Shan Li, Feng Jin and Ang Zheng
    Citation: Breast Cancer Research 2024 26:60
  40. Patients with hormone receptor positive breast cancer are recommended at least five years of adjuvant endocrine therapy, but adherence to this treatment is often suboptimal. We investigated longitudinal trends...

    Authors: Kirsten M. Woolpert, Julie A. Schmidt, Thomas P. Ahern, Cathrine F. Hjorth, Dóra K. Farkas, Bent Ejlertsen, Lindsay J. Collin, Timothy L. Lash and Deirdre P. Cronin-Fenton
    Citation: Breast Cancer Research 2024 26:59
  41. Authors: Muhammad Hasan Bashari, Fengjuan Fan, Sonia Vallet, Martin Sattler, Melissa Arn, Claudia Luckner-Minden, Henning Schulze-Bergkamen, Inka Zörnig, Frederik Marme, Andreas Schneeweiss, Michael H. Cardone, Joseph T. Opferman, Dirk Jäger and Klaus Podar
    Citation: Breast Cancer Research 2024 26:58

    The original article was published in Breast Cancer Research 2016 18:26

  42. Breast cancer continues to pose a substantial worldwide health concern, demanding a thorough comprehension of the complex interaction between cancerous cells and the immune system. Recent studies have shown th...

    Authors: Sahar Safaei, Manouchehr Fadaee, Omid Rahbar Farzam, Amirhossein Yari, Elham Poursaei, Cynthia Aslan, Sahar Samemaleki, Dariush Shanehbandi, Behzad Baradaran and Tohid Kazemi
    Citation: Breast Cancer Research 2024 26:57
  43. Patient-derived organoid models of estrogen receptor-positive (ER+) breast cancer would provide a much-needed tool to understand drug resistance and disease progression better. However, the establishment and l...

    Authors: Michael U J Oliphant, Dipikaa Akshinthala and Senthil K. Muthuswamy
    Citation: Breast Cancer Research 2024 26:56
  44. Breast cancer-related leptomeningeal disease (BC-LMD) is a dire diagnosis for 5–8% of patients with breast cancer (BC). We conducted a retrospective review of BC-LMD patients diagnosed at Moffitt Cancer Center...

    Authors: Gerald Wallace, Ronak Kundalia, Ethan Vallebuona, Biwei Cao, Youngchul Kim, Peter Forsyth, Aixa Soyano, Inna Smalley and Yolanda Pina
    Citation: Breast Cancer Research 2024 26:55
  45. Fibroblast growth factors (FGFs) control various cellular functions through fibroblast growth factor receptor (FGFR) activation, including proliferation, differentiation, migration, and survival. FGFR amplific...

    Authors: Feng Chi, Jason I. Griffiths, Aritro Nath and Andrea H. Bild
    Citation: Breast Cancer Research 2024 26:54
  46. Authors: Jing Qian, Yanxia Ma, William M. Tahaney, Cassandra L. Moyer, Amanda Lanier, Jamal Hill, Darian Coleman, Negar Koupaei, Susan G. Hilsenbeck, Michelle I. Savage, Brent D. G. Page, Abhijit Mazumdar and Powel H. Brown
    Citation: Breast Cancer Research 2024 26:53

    The original article was published in Breast Cancer Research 2024 26:23

  47. Benign breast disease (BBD) and high mammographic breast density (MBD) are prevalent and independent risk factors for invasive breast cancer. It has been suggested that temporal changes in MBD may impact futur...

    Authors: Maeve Mullooly, Shaoqi Fan, Ruth M. Pfeiffer, Erin Aiello Bowles, Máire A. Duggan, Roni T. Falk, Kathryn Richert-Boe, Andrew G. Glass, Teresa M. Kimes, Jonine D. Figueroa, Thomas E. Rohan, Mustapha Abubakar and Gretchen L. Gierach
    Citation: Breast Cancer Research 2024 26:52

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.4 - 5-year Impact Factor
    1.764 - SNIP (Source Normalized Impact per Paper)
    2.408 - SJR (SCImago Journal Rank)

    2023 Speed
    20 days submission to first editorial decision for all manuscripts (Median)
    129 days submission to accept (Median)

    2023 Usage 
    2,432,781 downloads
    1,561 Altmetric mentions